Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DSS
DSS logo

DSS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.582
Open
0.548
VWAP
0.56
Vol
83.53K
Mkt Cap
10.16M
Low
0.530
Amount
46.38K
EV/EBITDA(TTM)
--
Total Shares
18.38M
EV
42.93M
EV/OCF(TTM)
--
P/S(TTM)
0.24
DSS, Inc. is a multinational, public company. The Company operates its business through five divisions: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. The Product Packaging division operates through Premier Packaging Corporation, Inc., which markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through its operating company, American Pacific Bancorp, Inc., which represents its banking and financing business line. The Direct Marketing is specialized in marketing and distributing its products and services through its subsidiary and partner network, using the gig economic marketing strategy as a form of direct marketing.
Show More

Events Timeline

(ET)
2026-05-08
17:10:00
DSS Annual Report Contains Going Concern Audit Opinion
select
2026-02-04 (ET)
2026-02-04
08:40:00
DSS Prices Public Offering Expected to Raise $1M
select
2026-02-03 (ET)
2026-02-03
20:30:00
Aegis Capital Acts as Sole Underwriter for Offering
select
2025-06-24 (ET)
2025-06-24
08:33:48
DSS' Impact BioMedical announces strategic merger with Dr. Ashley's
select
2025-05-22 (ET)
2025-05-22
08:32:59
DSS reports Q1 EPS (55c) vs. (58c) last year
select
2025-04-24 (ET)
2025-04-24
08:36:31
Sentinel Brokers Company receives FINRA approval to act as underwriter
select
2025-02-26 (ET)
2025-02-26
08:36:20
DSS announces sale of Celios to Impact BioMedical
select
2024-08-26 (ET)
2024-08-26
16:21:49
DSS CEO Heuszel steps down, COO Jason Grady named as interim
select

News

Newsfilter
9.5
05-08Newsfilter
DSS Announces 2025 Fiscal Year Audit Report with Going Concern Qualification
  • Audit Opinion Disclosure: DSS, Inc. received an audit opinion from HTL International LLC in its 2025 fiscal year report, which includes a 'going concern' qualification, indicating potential financial uncertainties that could impact investor confidence and stock performance.
  • Compliance Announcement Requirement: Under NYSE American LLC Company Guide Section 610(b), DSS is required to publicly disclose this audit opinion, although the announcement does not amend the financial statements or annual report for the fiscal year 2025, demonstrating the company's commitment to transparency in compliance.
  • Diversified Business Model: DSS operates as a multinational company across various sectors including product packaging, biotechnology, commercial lending, and securities investment management, aiming to unlock value through the development of high-growth subsidiaries and strategic IPOs, despite current audit challenges.
  • Forward-Looking Statement Risks: The company notes that forward-looking statements may be subject to various risks and uncertainties, which could lead to actual results differing significantly from expectations, potentially further affecting investor confidence in the company's future prospects.
moomoo
5.0
04-29moomoo
Insider at DSS Inc (DSS.US) Plans to Sell $23.06 Million in Common Stock via Form 144
  • Stock Sale Announcement: DSS Inc. plans to sell 31.94 million shares of its common stock.

  • Market Value: The total market value of the shares being sold is approximately $23.06 million.

moomoo
8.5
03-30moomoo
ALSET INC - CLOSING OF DEAL DEPENDENT ON DSS STOCKHOLDER APPROVAL - SEC FILING
  • Deal Closing: The ALS ETINC deal is set to close contingent upon shareholder approval.
  • SEC Filing: The company has filed necessary documents with the SEC regarding the deal.
moomoo
8.5
03-30moomoo
ALSET INC - AIL TO PROVIDE $2.45 MILLION LOAN TO DSS FOR CONVERTIBLE NOTE AND WARRANTS TO ACQUIRE 16,554,055 DSS SHARES - SEC FILING
  • Loan and Securities Details: A company has secured a loan of $2.45 million for convertible notes and warrants, which will halt the purchase of 16,554,055 shares.

  • Regulatory Filing: The information regarding the loan and share purchase has been disclosed in a SEC filing.

moomoo
7.5
03-30moomoo
ALSET INTERNATIONAL LIMITED SIGNS SECURITIES PURCHASE AGREEMENT WITH DSS INC ON MARCH 26, 2026 - SEC FILING
  • Company Announcement: A company named ALSENT INC has entered into a securities purchase agreement with DSS, Inc.
  • Date of Agreement: The agreement was finalized on March 26, 2026, indicating a future transaction.
Benzinga
8.5
03-05Benzinga
Impact Biomedical Amends Merger Agreement with Dr Ashleys Bio Labs
  • Significant Stock Surge: Impact Biomedical shares soared 86.28% in after-hours trading to $0.77, indicating strong market optimism following the amendment of its merger agreement with Dr Ashleys Bio Labs, reflecting investor confidence in future growth prospects.
  • Merger Agreement Amendment: On February 27, Impact Biomedical extended the end date of its Merger and Share Exchange Agreement from March 31, 2026, to July 1, 2026, providing the company with additional time to meet compliance requirements and ensuring a smoother transaction process.
  • Share Allocation Details: Under the revised terms, Dr Ashleys Bio Labs will issue 169.5 million ordinary shares to its sole shareholder at closing, representing 94.20% of the total issued shares, which will significantly impact the company's equity structure and potentially enhance its market appeal.
  • Market Performance Analysis: Despite the recent stock rebound, Impact Biomedical's market capitalization stands at $43.24 million, with a 71.30% decline over the past 12 months, indicating that the company requires clear recovery signals to regain investor confidence and attract capital inflows.

Valuation Metrics

The current forward P/E ratio for DSS Inc (DSS.A) is 0.00, compared to its 5-year average forward P/E of -1.75. For a more detailed relative valuation and DCF analysis to assess DSS Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.75
Current PE
0.00
Overvalued PE
-0.45
Undervalued PE
-3.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.60
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.05
Undervalued EV/EBITDA
-12.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.94
Current PS
0.00
Overvalued PS
1.95
Undervalued PS
-0.06

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

predict most bullish ticker this month
Intellectia · 114 candidates
Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 65One Month Predict Return: >= 10.0%
Ticker
Name
Market Cap$
top bottom
SPKL logo
SPKL
Spark I Acquisition Corp
98.18M
APXT logo
APXT
Apex Treasury Corp
458.22M
AMST logo
AMST
Amesite Inc
8.37M
CZFS logo
CZFS
Citizens Financial Services Inc
278.29M
JNJ logo
JNJ
Johnson & Johnson
571.52B
CRBU logo
CRBU
Caribou Biosciences Inc
184.58M
positive macd and expanding
Intellectia · 1739 candidates
Region: USList Exchange: XNYS, XNAS, XASEMacd: positive, bullish
Ticker
Name
Market Cap$
top bottom
WTO logo
WTO
UTime Ltd
1.13M
PZG logo
PZG
Paramount Gold Nevada Corp
163.38M
DVA logo
DVA
DaVita Inc
9.26B
GORO logo
GORO
Gold Resource Corp
250.87M
CDT logo
CDT
CDT Equity Inc
2.68M
DSS logo
DSS
DSS Inc
11.68M

Whales Holding DSS

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is DSS Inc (DSS) stock price today?

The current price of DSS is 0.553 USD — it has decreased -1.25

What is DSS Inc (DSS)'s business?

DSS, Inc. is a multinational, public company. The Company operates its business through five divisions: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. The Product Packaging division operates through Premier Packaging Corporation, Inc., which markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through its operating company, American Pacific Bancorp, Inc., which represents its banking and financing business line. The Direct Marketing is specialized in marketing and distributing its products and services through its subsidiary and partner network, using the gig economic marketing strategy as a form of direct marketing.

What is the price predicton of DSS Stock?

Wall Street analysts forecast DSS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DSS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is DSS Inc (DSS)'s revenue for the last quarter?

DSS Inc revenue for the last quarter amounts to 4.13M USD, decreased -23.80

What is DSS Inc (DSS)'s earnings per share (EPS) for the last quarter?

DSS Inc. EPS for the last quarter amounts to -1.62 USD, decreased -65.09

How many employees does DSS Inc (DSS). have?

DSS Inc (DSS) has 102 emplpoyees as of May 10 2026.

What is DSS Inc (DSS) market cap?

Today DSS has the market capitalization of 10.16M USD.